MAD2L1 and idiopathic pulmonary fibrosis: The data suggested that alleviation of mitochondrial damage in alveolar epithelial cells through augmentation of MAD2L1 may be served as a novel therapeutic strategy for a cure of idiopathic pulmonary fibrosis.